Herpes zoster (HZ) is a common, painful and debilitating disease caused by the reactivation of latent varicella-zoster virus in ganglia. This clinical event occurs more frequently in the elderly and those who are immunocompromised. 
INTRODUCTION
The varicella-zoster virus (VZV) is a DNA virus that belongs to the Herpesviridae family, subfamily Alphaherpesvirinae [1, 2] . After primary infection with VZV, it remains dormant in the dorsal root or cranial nerve sensory ganglia. When reactivation occurs it causes herpes zoster (HZ), also known as shingles, usually characterized by a vesicular eruption with severe pain in a single dermatome segment [2] [3] [4] [5] .
The course of acute HZ episodes can be complicated by post-herpetic neuralgia (PHN), which is a painful and debilitating condition defined as a chronic neuropathic resilient pain that persists for 3 months or more from the initial onset of the rash [6, 7] . The risk of VZV reactivation increases with the decline of cell-mediated immunity, particularly due to the aging [3] . In addition, individuals who are immunocompromised due by certain diseases, such as hematologic malignancies and solid cancers have an increased risk for a higher incidence and severity of HZ and its neurologic and ophthalmologic complications and visceral dissemination [8] [9] [10] [11] [12] [13] [14] [15] [16] . The risk of HZ and its complications is also higher in patients with autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and Crohn's disease due to both the pathologic process and to their immunosuppressive treatments [17] [18] [19] [20] [21] [22] [23] [24] .
The annual incidence rates of HZ are similar across countries, ranging from 3 to 5 per 1000 people in North America, Europe and Asia-Pacific [25] . In all countries, HZ shows a similar age-specific epidemiologic pattern, with a steep increase in the incidence rate in those aged 50 years or more, with up to 8-12 HZ cases per 1000 persons in those aged 80 years or more [25] . Nearly 50% of individuals aged 85 years or more have experienced HZ [3] . The incidence of PHN also increases with age, ranging between 5% and about 30% in the adult population and between 25% and 50% in adults aged 50 years or more [25] .
Herpes zoster and PHN affect the health-related quality of life and induce a substantial economic burden [26] . PHN has been reported to have an impact on physical, psychological, functional and social aspects of patients' lives causing interference with daily activities. HZ and PHN cannot be managed satisfactorily with the currently available treatments and severe cases require extensive healthcare resources, particularly for specialist consultations, diagnostic examinations, and sometimes, hospitalization [27] . In the same year, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) authorized Zostavax for the prevention of both HZ and PHN [29] . In March 2011, the FDA extended the indication to include adults aged between 50 and 59 years [30] . Zostavax is currently the only HZ vaccine approved for use in the United States (US) and in Europe [29, 31] . After its licensure in the US, the Advisory Committee on Immunization Practices (ACIP) recommends the use of Zostavax for prevention of HZ and its complications among adults aged C60 years [32] . In this age group the vaccine is reimbursed by private health insurance or through public program.
Advisory Committee on Immunization
Practices also considered the use of HZ vaccine among adults aged 50 through 59 years [30] [34] . 
HZ VACCINE EFFECTIVENESS IN IMMUNOCOMPETENT SUBJECTS
Since licensure, the effectiveness of HZ vaccine has been assessed in three retrospective studies in immunocompetent subjects in the US ( for vaccinated subjects (VE: 51%; 95% CI 50%; 53%). The effectiveness was confirmed for all age groups and in patients with chronic diseases, but unlike the previous study, the VE seemed to lower in those aged 60-69 years compared with those aged C70 years [37] . Four smaller studies were conducted in immunocompetent populations [38] [39] [40] [41] . The risk of recurrent HZ did not significantly differ between vaccinated and unvaccinated individuals in a matched cohort study among elderly individuals aged C60 years who had had a recent episode of HZ [38] . Another study reported 
REAL-WORLD SAFETY OF HZ VACCINE
Since its licensure, the safety profile of the HZ vaccine has been investigated in large studies conducted in ''real-world'' settings. The results have been generally consistent with those reported in clinical trials, with no safety concerns detected, in both the general population and in certain patient groups with immune-mediated conditions. In one study, using data from the Vaccine Safety Datalink Project it was reported that the HZ vaccine is safe and well-tolerated in subjects aged C50 years, confirming pre-licensure results [52] . In addition, in this ''real-world'' setting, no increased risks for cerebrovascular, cardiovascular or neurological events were observed [52] . The optimal safety profile was also established: results from a large cohort study in about 29,000 vaccinated individuals aged C60 years enrolled in the Kaiser 
